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Objective: This study was conducted to determine the efficacy and safety of stent grafts in the treatment of thoracic aortic
aneurysms and dissections.
Method: Our health technology assessment method combined a critical review of the literature with experts’ opinions.
Several databases, useful Web sites, and the gray literature were searched from January 1995 to December 2004. Some
manually retrieved major articles published in 2005 were also included. The draft report was submitted to and discussed
by a working group of 12 members nominated by relevant medical societies. The amended report was submitted to a
multidisciplinary group of 12 peer reviewers for comment.
Results: Endovascular stent grafting (ESG) repair for lesions of the thoracic aorta, including aneurysms, dissections, and
aortic isthmus ruptures, is probably beneficial in terms of operative mortality and severe morbidity, with an incidence of
paraplegia of 2.1% (range 0%-7%) for ESG vs 5% (range, 3%-15%) for surgery, provided that there is a rigorous
medium-term assessment and that anatomic factors are favorable. A proximal neck length of at least 2 cm is needed to
insert the stent graft. Indications for ESG in thoracic aortic aneurysm and dissection are similar to those for surgery.
Endovascular stent grafting is particularly appropriate in patients with multiple traumas to the thoracic aorta in whom
concomitant lesions are a contraindication to open surgery. Endovascular stent graft repair can only be done in public or
private centers with expertise in both endovascular and surgical procedures and with adequate technical facilities. Patients
should be informed of the advantages and drawbacks of both methods. A multidisciplinary discussion should address
risks of converting to open surgery and possible need for a cardiopulmonary bypass. Patients should be monitored
annually by computed tomography scan or magnetic resonance imaging and plain radiographs because long-term results
are uncertain (possible stent graft deterioration, onset of aortic disease). They should be told of the need for surveillance
and possible further treatment.
Conclusions: A prospective registry of all thoracic aorta procedures (endovascular treatment, open surgery, thoracic ESG
plus extra-anatomic bypass) needs to be set up. All practitioners and stent graft manufacturers should contribute to this
registry. It should include information on patient monitoring in order to (1) select patients who could be treated by ESG
repair, (2) assess the feasibility of a randomized controlled study comparing ESG and surgery, (3) assess the medium-term
outcome of different devices, and (4) obtain a better understanding of the health economics aspects. ( J Vasc Surg 2008;
47:1099-1107.)The two main degenerative diseases affecting the tho-
racic aorta (TA) are aneurysms (TAAs) and dissections
(TADs). If left untreated, they may be life threatening.
Treatment is medical or surgical, or both. The aim of
medical treatment is to control blood pressure, but its
efficacy is limited once symptoms have appeared (impend-
ing aneurysms, back pain, malperfusion syndrome) or when
the degree of true lumen constriction exceeds two-thirds.
At this stage of the disease, open surgery is the gold
standard treatment; however, only patients with an accept-
able surgical risk can benefit from open surgery because it
may involve cardiopulmonary bypass. Endovascular stent
grafting (ESG) might prove to be an acceptable alternative
to open surgery.
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doi:10.1016/j.jvs.2007.11.021One of the main activities of the Haute Autorité de
Santé (HAS), or French National Authority for Health, is
to assess drugs, medical devices, and procedures to encour-
age their proper use by professionals and to provide health
authorities with the information they require to make de-
cisions on reimbursement by National Health Insurance.
The French Society of Vascular Surgery therefore asked
HAS to assess the efficacy and safety of ESG in the treat-
ment of TAAs and TADs. This article is based on a HAS
report published in February 2006.
METHOD
The assessment report on ESG for TAAs and TADs was
produced using an established method combining a critical
appraisal of the literature and the opinion of a panel of
experts recruited from several medical societies. We per-
formed an electronic search of several bibliographic data-
bases (MEDLINE, EMBASE, and PASCAL; articles in
English or French) from January 1995 to December 2004
and consulted useful Web sites and the grey literature (eg,
conference reports, fact sheets, patent applications, sympo-
sia, technical reports, etc). A manual search was used to
retrieve major articles published in early 2005.
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analysis:
1. comparative diagnostic and therapeutic studies on TA
disease, regardless of sample size;
2. safety and efficacy studies on the treatment of athero-
matous aneurysms, unruptured type B or traumatic
dissections, intramural hematomas, and penetrating
aortic ulcers (TA segments II and III), regardless of
Table I B. Results of the literature search
Articles, No.
Articles retrieved 529
Articles analyzed 281
Articles cited in report 58
Descending thoracic aorta treatment 34b
Emergency treatment (ruptures and traumas) 10
Disease spread to the aortic arch. 8
Reviews 6
bIncluding a double study.
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we excluded studies of homemade stent grafts because of
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lance monitoring.
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review of the literature that was submitted for discussion to
a multidisciplinary working group of 15 members consist-
ing of cardiologists, cardiac surgeons, vascular surgeons,
vascular physicians, radiologists, engineers, anesthesiolo-
gists, and an account manager. Working group members
were nominated by the relevant medical societies. An anal-
ysis of French ESG practice based on data from the Pro-
gramme of Medicalization of Information Systems (PMSI)
and from the Common Classification of Medical Proce-
dures (CCAM), and on a description of care at Saint Joseph
Hospital in Marseilles was included in the report. The
amended report was then submitted to a multidisciplinary
group of 12 peer reviewers for comment.
RESULTS
Study quality. Seven nonrandomized, comparative
studies (evidence level 2) were included in the 58 articles
analyzed (Table II).1-7 Five of these studies compared
surgical and endovascular treatments, one compared med-
ical and endovascular treatments, and one concerned imag-
ing techniques. Only the studies by Brandt et al5 and
Nienaber et al2 compared ESG with conventional surgery
in two groups of statistically comparable patients, either by
identification of similar subpopulations or prospectively.
In the three other studies of ESG vs surgery, the
demographic and clinical characteristics of the two groups
of patients differed, with the ESG patients presenting a high
comorbidity rate, such as high blood pressure, heart dis-
ease, or chronic pulmonary obstructive disease.1,3,4 In the
study by Ehrlich et al,1 all the patients undergoing surgery
could have been eligible for ESG; however, whereas all ESG
patients had either coronary artery disease or a history of
myocardial infarction, only 53% of the surgical patients did.
In the study by Najibi et al,3 the proportion of men and
women was not the same in both groups. None of these
three studies accounted for confounding factors.1,3,4 The
study by Bortone et al6 compares ESG with medical treat-
ment but makes no mention of a comparison between the
Table II. Nonrandomized comparatives studies design
First author Treatment Patient
Ehrlich,1 1998 First commercial ESG vs surgery 10
Nienaber,2 1999 ESG vs surgery 12
Najibi,3 2002 ESG vs surgery 46
Doss,4 2003 ESG vs surgery with cardio-
pulmonary assistance
26
Brandt,5 2004 ESG vs surgery 22
Bortone,6 2004 ESG vs medical treatment 110
Rocchi,7 2004 Diagnostic role of intrasurgical
TEE and pre-op angiography
in ESG patients
42
ESG, Endovascular stent grafting; TAD, thoracic aorta dissection; TEE, trangroups under study.Of the 58 studies analyzed, 34 (59%) were noncom-
parative cohort studies. The study of Ramaiah et al,8 in
which patients were split into two distinct series according
to year of ESG treatment, was the only exception even if it
was not a genuine comparative study. Whether the study
was prospective or retrospective was specified in 22 of 34
(65%) studies (8 prospective, 14 retrospective), and the
primary end point was clearly stated in 32 (94%). The
number of patients to be included was rarely calculated:
only three studies (9%) reported intention-to-treat results,
and only nine (26.5%) performed an intention-to-treat
analysis. Even if the methodologic quality of these cohort
studies was rather poor, 31 (91%) reported results that
directly concerned the primary end point. All of the studies
addressed the clinical relevance of ESG and its use as a
routine procedure. Patients formed representative samples
of the populations usually treated for these diseases and not
of the general population.
Efficacy of endovascular treatment of descending
thoracic aorta disease regardless of cause. The technical
success rate was mentioned in 31 studies and ranged from
77% to 100% according to study. The overall success rate
was 94.6% (Table III).1-3,7,9-31 Five studies defined tech-
nical success at the outset.3-7,28,32 According to Czerny
et al12 and Taylor et al,29 technical success is “perfect ESG
deployment without primary leak.” Leurs et al20 completed
this definition as follows: “successful ESG deployment in
the absence of primary endoleak and intra-surgical compli-
cation.” However, the latest definitions are given by Erbel
et al,23 “insertion and successful deployment of ESG with-
out surgical conversion necessity nor per-surgical mortality,
in the absence of type 1 or 3 endoleak, till the 24th post
surgical hour,” and by Najibi et al,3 who reported the
technical success rate at 30 days using the definition given
by the Society of Vascular Surgery/International Society
for Cardiovascular Surgery. Themean technical success rate
in these five studies defining success rate was 88.8%
(Table IV).
Seven studies reported blood loss. Among them, 6
Description of patient population
Two historically successive groups of patients
Prospective study in TAD patients (2 centers)
Historical controls (patients treated by surgery who were
retrospectively considered to be good candidates for ESG)
Nonrandomized, based on surgical risk
No significant difference in the demographic and clinical
characteristics of both groups of patients
Retrospective study of 4 groups: 1, ESG for atherosclerotic
aneurysms; 2, ESG for traumatic lesions; 3, ESG for
complicated type B dissections; 4, medication
Long-term study in patients with a chronic type B dissection
on whether intra-op TEE modifies the planned ESG
intervention
hageal echocardiography.s, No.studies have quantified a total of 372 patients with a mean
17
tic dis
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The mean surgical conversion rate, reported in 26 studies,
was 1.4% (range, 0%-7.4%). Seven studies reported the ESG
procedure lasted an average of 118 minutes (range, 37-580
minutes). Themean length of hospital stay in 17 of 19 studies
documenting this variable was 6.6 days (range, 2.8-10 days)
for a total of 542 patients. One study reported a mean length
of stay of just 4 days.9 In contrast, eight studies mentioned a
mean length of stay in the intensive care unit of 2.9 days
Table III. Technical success rate
First author
Patients, No.
T
Total Elective Emergency
Bell,9 2003 67 42 25
Bergeron,10 2003 33 32 1
Bortone,6 2004 110
Criado,11 2002 47
Czerny,12 2004 54
Dessl,13 2004 84 66 18
Destrieux-Garnier,14 2004 32 21 11
Doss,4 2003 26
Ehrlich,1 1998 10
Fattori,15 2003 70 56 14
Hansen,16 2004 60 47 13
Heijmen,17 2002 27 27
Lepore,18 2002 43 20 23
Leprince,19 2003 26
Leurs,20 2004 443 266 155
Lonn,21 2003 20
Makaroun,22 2004 142
Erbel,23 2003 94
Najibi,3 2002 46
Neuhauser,24 2004 31 18 13
Nienaber,2 1999 12
Orend,25 2003 74 48 26
Ouriel,26 2003 31 26 5
Ramaiah,8 2003 46
Ramaiah,8 2003 37
Rocchi,7 2004 42
Scharrer-Pamler,27 2003 45 34 11
Schoder,28 2003 28
Taylor,29 2001 37 19 18
Totaro,30 2002 32
Tse,31 2004 36
Total 1885
Table IV. Technical success rate in studies defining techn
Indication
First author Patients, No. TAA TAD Trauma
Czerny,12 2004 54 54 0 0
Leurs,20 2004 443 249 131 50
Erbel,23 2003 94 NA NA NA
Najibi,3 2002 19 NA NA NA
Taylor,29 2001 37 18 6 5
Total 647
NA, Not available; TAA, thoracic abdominal aneurysm; TAD, thoracic aor(range, 1.5-4.3 days) for a total of 384 interventions.Death after endovascular treatment. The mean 30-
day mortality rate in 1756 patients from 31 studies was
6% (range, 0%-15%). Overall mortality, defined as deaths
30 days and during follow-up, was derived from 21
studies and was 0% to 28%. Of these 21 studies, 17 gave a
mean follow-up that was used to calculate an overall mor-
tality rate of 11.7% over an average of 18.4 months of
follow-up. Seven studies provided actuarial survival rates,
one of which reported a 2-year survival rate of50%.23 The
cal success rate,
No. (%)
Conversions,
No. (%)
Early death,
No. (%)
Endoleaks,
No. (%)
67 (100) 5 (8) 5 (8)
32 (97) 3 (9) 0
06 (96.4) 1 (0.9) 4 (3.6)
46 (98) 1 (2.1)
51 (94.4) 0 2 (3.7) 15 (28.9)
73 (87.2) 1 (2.5) 1 (2.5) 4 (11)
32 (100) 0 3 (9) 9 (28)
20 (77)
10 (100) 0 1 (10) 2 (20)
68 (97) 5 (7.4) 1 (1.5) 5 (7.4)
59 (98.3) 2 (3.4) 9 (15) 14 (24)
26 (96)
43 (100) 0 3 (7) 9 (21)
26 (100) 1 (3.8) 2 (7.7)
90 (87-89) 0 41 (9.3)
20 (100) 0 3 (15) 2 (10)
40 (98) 1 (1) 2 (1.5) 6/68 at 2 y (9)
80 (85)
46 (100)
30 (95) 6 (19) 13 (45); type I,
7 (23)
12 (100) 0 0 0
74 (100) 5 (6.7) 7 (9.5)
31 (100) 1 (3.2) 4 (12.9) 14 (45)
46 (100) 0 2 (4) 4 (8)
37 (100) 0 4 (10.8) 2 (5.4)
42 (100) 0
45 (100) 0 3 (6.7) 8 (17.8)
28 (100) 0 0 9 (32)
36 (97.3) 0 3 (8)
32 (100) 1 (3.1) 0 3 (10)
36 (100) 2 (5.6) 0 3 (8.3)
84 (94.6)
uccess (type I)
Circumstances
ther Elective Emergency Technical success rate, No. (%)
0 NA NA 51 (94.4)
13 266 155 393 (88.7)
NA NA NA 80 (85)
NA NA NA 17 (89)
8 19 18 36 (97.3)
577 (89.2)
section.echni
1
3
1ical s
Osurvival rate in the other six studies was 80% at 2, 3, or 5
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follow-up, 25 15 months) in the study by Fattori et al.15
The 1-year survival rates were 80% and 90% in two
studies20,25 and 47% and 84% in two others.24,26
Emergency patients were at much higher risk of death
than those receiving elective treatment, whether in the case
of ESG or open surgery. Of the 27 cohort studies that
included surgical and endovascular repair, 11 distinguished
death after elective and emergency surgery. Surgery was not
reviewed in other articles. Emergency patients were a het-
erogeneous group, including traumatic ruptures with low
mortality and TAA or TAD ruptures in patients with mul-
tiple comorbidities. A single study defined emergency treat-
ment as treatment48 hours of admission, symptomatic or
fissured aneurysms, complicated Stanford type B aortic
dissections, and traumatic aortic sections.9 The mean 30-
day mortality rate in these 11 studies was 5.9% (range,
0%-16%) in electively treated patients and 16% (range,
2.5%-23%) in emergency cases. The overall mortality rate in
seven studies was 13.3% (range, 4%-45%) in electively
treated patients and 28.2% (range, 5%-38.5%) in emer-
gency cases for a median follow-up of 20.5 months.
Endoleaks after endovascular treatment. Endoleaks
are a specific complication of endovascular treatment. The
HAS report used the endoleak classification given by White
et al33 for TAAs. Type I endoleaks are defined as an
incomplete or ineffective seal at the proximal or distal
end(s), or both, of the graft, and type II endoleaks as a
retrograde blood flow from arterial branches. In TADs, the
false lumen can also be perfused from distal re-entries and
blood flow can circulate in a retrograde way; therefore, we
prefer to use “false channel perfusion” instead of “en-
doleaks” in TADs.
The rate of early endoleaks was reported in 18 studies
covering all types of TA disease. The mean rate was 10.5%
(range, 0%-45%) for a total of 796 patients. No endoleaks
were observed in three studies totalling 68 patients. The
type of endoleak was specified in eight of 18 stud-
ies.9,15,18,23,26-28,31 In patients with an endoleak (13.4% of
371 patients), 76% of the endoleaks were type 1 leaks
Table V. Endoleaks according to indication
First author Patients, No.
Ind
TAA TAD
Bavaria,34 2004 50 48 2
Bell,9 2003 67 44 14
Bortone,6 2004 110 43 43
Destrieux-Garnier,14 2004 32 3 17
Lepore,18 2002 43 14 16
Leurs,20 2004 443 249 131
Lonn,21 2003 20 0 20
Nienaber,2 1999 12 0 12
Taylor,29 2001 37 18 6
Total 814 419 261
TAA, Thoracic abdominal aneurysm; TAD, thoracic aortic dissection.(remaining endoleaks at the end of the procedure), 20%were type 2, and 4% were type 3. No early type 4 endoleaks
were observed.
Late endoleaks were reported in 18 further studies
totalling 907 patients. Themean rate was 7.5% for amedian
follow-up of 17.9 months. Three studies totalling 93 pa-
tients reported a complete absence of endoleaks for a mean
follow-up of at least 12 months.2,3,10 Only six studies
specified endoleak type: 61.8% were type 1 leaks, 23.5%
were type 2 leaks, and 14.7% were type 3 leaks. No study
mentioned a type 4 endoleak caused by porosity of the graft
material.
Of the 21 selected studies specifying the disease being
treated and distinguishing TAAs and TADs, nine reported
an endoleak rate but without specifying the disease, three
did not distinguish early and late endoleaks,7,24,32 and only
nine distinguished endoleaks in TAAs and circulating false
lumens in TADs. The 814 procedures in these nine studies
concerned 419 TAAs, 261 TADs, 87 aortic traumas (either
TAA or TAD), and 47 procedures for other causes (Table
V).2,6,9,14,18,20,21,29,34 No endoleaks occurred in two stud-
ies of TAAs6,18 and two studies of TADs.2,31 Themean rate
of endoleaks was highly similar for TAAs at 10.3% (range,
4%-30%) and TADs at 11.1% (range, 7%-47%). With a total
of 32 procedures, the total rate of endoleaks for TAD was
6.25%.
Other complications after endovascular treatment.
Technical, neurologic, and other complications are sum-
marized in Table VI. Other types of complications were
mentioned in 17 studies totalling 900 patients, the three
main being renal insufficiency, respiratory complications,
and scar complications.
DISCUSSION
Methodologic limitations. Our assessment revealed
the many methodologic limitations of studies on endovas-
cular treatment of diseases of the TA. These limitations
concerned:
● Study design.Most studies were cohort studies, includ-
ing 27 retrospective (evidence level 5) and 11 prospec-
n
Follow-up, mean
months (range)
Endoleaks, No. (%)
uma Other TAA TAD
12 14 (28) 0
3 6 17 (2-64) 3 (4) 2 (14.3)
4 0 20.8  10 (1-55) 0 3 (7)
5 7 13.5 (2-28) 1 (30) 8 (47)
0 13 19 (0-34) 0 2 (12.5)
0 13 (1-60) 23 (9.1) 11 (8)
0 0 13 (2-28) — 2 (10)
0 0 12 — 0
5 8 17.5 (6-45) 2 (9.1) 1 (8)
7 47 15.6 43 (10.3) 29 (11.1)icatio
Tra
2
5
8tive (level 3); six studies were reviews.
ost-tr
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included an open surgery group (level 2), a compari-
son with ESG was not possible because of patient
heterogeneity in demographic characteristics and dis-
ease severity. Studies often did not specify patient
selection criteria and disease severity, distinguish aortic
aneurysms and dissections from different causes, de-
scribe marginal patients, or provide information on
loss to follow-up. Results for TAAs and acute and
chronic TADs and for emergency and elective treat-
ment were seldom distinguished.
● Outcomes. Events and technical success were rarely
defined: only six of 31 studies on technical success pro-
vided a definition. Few studies reported long-term results
for ESG. Only three studies had a mean follow-up of2
years. The durability of stent grafts is thus uncertain
Table VI. Complications
Complication
Studies,
No.
Patients,
No.
Comp
%
Technical complications other
than endoleaks
Vascular access complications 14 803 Mean,
ESG fracture 3 208 5.3 in
ESG migration 8 525 Mean,
Neurologic complications
Paraplegia 24 1480 Mean,
Stroke 18 836 Mean,
Other neurologic complications 3 228 Mean,
Nontechnical and non-neurologic
complications
Severe renal failure or requiring
dialysis
11 501
Respiratory complications 7 448 Mean,
Scar complications 6 220 Total,
Myocardial infarction 2 121
Post-transplantation syndrome 2 115
Retrograde dissection 3 180 Mean,
ESG, Endovascular stent grafting; MI, myocardial infarction.
aIn the study by Orend et al,25 4 patients (5%) required mechanical ventilat
(1%) patients, respectively, required assisted ventilation for 48 hours.
bIn the study by Fattori et al,15 81% of 68 patients presented a transient p
protein, and moderate hyperthermia.over the long-term.Our assessment of clinical outcomes was based on 42
studies, most of which were cohort studies. Seven of these
studies compared endovascular and conventional surgical
treatment but nearly always in patient groups with dissim-
ilar characteristics. The outcomes investigated were death
at 30 days, paraplegia rate, operative time, intraoperative
blood loss, and average length of stay in hospital.
Outcomes for endovascular treatment of dissec-
tions of the thoracic aorta. During the last 30 years, the
prognosis of patients with aortic dissections has improved
substantially. The European Echocardiographic Coopera-
tive Study Group has reported 1-year post-ESG survival
rates of 52%, 69%, and 70% and 2-year survival rates of 48%,
50%, and 60% for DeBakey types I, II (Stanford type A) and
III (Stanford type B) dissections, respectively.23 One-year
survival rates of 34% and 85% for Stanford type A and B
on rate,
ge) Comment
1.4-14) 47 complications; lesions: iliac artery dissections,4,14
primitive iliac artery perforations,17 femoral artery
dissections and/or rupture32 and iliac artery
ruptures.10,15,25
atients No fractures in 2 studies24,34 (mean follow-up, 14.25
mon); 11 fractures (13%) in a study of 84
patients32 (mean follow-up, 15 mon).
No migration in 5 studies3,8,11,32,34; 11 instances of
migration in 543 patients in 4 studies
0-6.5) No paraplegia in 13 studies1,2,4,6,8,10,13,14, 26-30; 31
cases in 10 studies; similar rates of paraplegia for
elective and emergency surgery (5% and 4%, resp)
in 1 study9
1.4-20) No strokes in one study4; 38 strokes in 836 patients
in 17 studies
6 cases of neurologic complications, incl 1 each
transitional monoparesis15 and transitional
paraparesis24
26 cases of renal failure
44 cases of complications requiring mechanical
respiratory assistance4,18,24 or pneumonia-type
complications9a
Healing complications, incl 1 each groin hematoma,9
femoral arterial access thrombosis,11 groin
infection,4 groin hematoma or a superficial
infection,17 an inguinal lymphocele3
Isolated cases of acute coronary syndrome after 1 and
22 mon in these 2 studies: a MI without Q-wave11
and a nontransmural MI25
56 cases in a mean follow-up of 25 mon11,15b
6 cases
r 24 hours. In the studies by Doss et al4 and Lepore et al,18 2 (8%) and 6
ansplantation syndrome characterized by leukocytosis, elevated C-reactivelicati
(ran
5.8 (
208 p
2.0
2.1 (
4.5 (
2.6
5.2
9.8
8.2
3.3
ion fodissections, respectively, had been reported earlier.35 Be-
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cation between the true and false lumen (ie, the pressure
exercised over the wall within the false lumen), the prog-
nosis of noncommunicating and retrograde Stanford type
B dissections restricted to the descending aorta was better:
the 2-year survival rates were 80% and 86%, respectively.
Endovascular treatment provides better outcomes than
medical treatment. The International Registry of Acute
Aortic Dissection (IRAD) study group reported mortality
rates of 53% and 9% for Stanford types A and B (DeBakey
I-III) dissections, respectively, after medical treatment
compared with 27% and 29% after surgical treatment in a
study of 464 patients.36
The morbidity rates of endovascular treated TAAs and
TADs were similar. Vascular access seemed to cause fewer
complications because of flexible arteries, provided the
stent graft was placed in the true lumen. Strokes after TADs
were less frequent than after TAAs owing to the absence of
atheromatous lesions of the aortic arch. However, supra-
aortic vessels could be the seat of dissection-induced malp-
erfusion. The paraplegia rate was no higher for TADs than
TAAs. Reports of aortic arch and ascending aorta retro-
grade dissection were rare.37-39 Lethal mechanical compli-
cations have been reported, including rupture and fistulas
between the aorta and esophagus or bronchus, related to
the uncovered part of the stent graft. The use of this type of
stent should be avoided.
Organization of endovascular treatment and surveil-
lance based on the expert panel’s opinion. Endovascular
treatment of TAAs and TADs should be performed in
expert centers where catheterization and endovascular pro-
cedures are routine. Multiple skills are required, including
knowledge of medical, surgical, and endovascular treat-
ments and their indications; clinical experience; and ability
to interpret the results of imaging examinations. High-
quality intensive care requires close cooperation between
cardiologists and radiologists. Nursing staff should be ex-
perienced in the surveillance of patients with instability or
complications arising from a surgical conversion or from a
need for respiratory or renal assistance or both. All sur-
geons should have a university qualification in the field and
have attended relevant continuous medical training ses-
sions. Their practice should have been certified in reference
centers.
Patient selection depends on anatomic and clinical
criteria to be discussed during multidisciplinary staff meet-
ings in order to assess the benefit–risk ratios of the treat-
ments offered.
Patients should be informed of the advantages and
drawbacks of each procedure and of the conditions of
long-term surveillance in order to be able to reflect on the
options and make an informed choice. Provision of infor-
mation to the patient will be put down in writing but does
not imply that the patient has understood the information.
The patient, or his or her family if appropriate, must give
informed consent for the chosen treatment.
Postoperative surveillance will depend on the patient’s
clinical condition. On discharge from the hospital, thepatient will be given a schedule of hospital visits and radio-
logic examinations, including computed tomography (CT)
scanning or magnetic resonance imaging (MRI) plus tho-
racic radiograph. The French Agency for the Safety of
Healthcare Products (AFSSAPS) has not yet issued guide-
lines for surveillance after endovascular treatment of TAAs
and TADs. The recommended schedule for the abdominal
aorta ESG should be applied in the meantime; that is,
examinations on discharge from hospital or after 1 month,
at 3 months if an early endoleak occurred, at 6, 12, 18, and
24 months, and yearly thereafter. Surveillance should be
tailored to the patient and depends on endoleak occurrence,
available equipment, and risks from radiation overexposure.
The working group recommended that for reproducibility
and reliability, radiologic examinations should be done when-
ever possible in the same center. Imaging reports should
record the maximum aneurysm diameter, permeability, stent
graft migration, periprosthetic leaks and, if appropriate, the
perfusion of the false lumen at both thoracic and abdominal
levels.
CONCLUSIONS
Endovascular treatment of thoracic aorta disease, in-
cluding aneurysms, dissections, and traumatic disruption, is
probably beneficial in terms of operative mortality and
severe morbidity (incidence of paraplegia, 2.1% [range,
0%-7%] for ESG vs 5% [range, 3%-15%] for surgery), pro-
vided there is a rigorous medium-term assessment and
provided that anatomic factors are favorable. In particular,
a proximal neck length of at least 2 cm is needed to insert
the stent graft. The indications for endovascular treatment
are the same as those for open surgery. Endovascular stent
grafting seems particularly appropriate in patients with
multiple thoracic traumas in whom concomitant lesions are
a contraindication to open surgery.
Treatment should be done in public or private centers
with expertise in both endovascular and surgical procedures
and with adequate technical facilities. Patients should be
informed of the advantages and drawbacks of both meth-
ods. Endovascular stent graft treatment should be subject
to prior multidisciplinary discussion, particularly with re-
gard to risks of conversion and need for a cardiopulmonary
bypass. Patients should be monitored annually by CT scan
or MRI plus plain radiograph because long-term results are
uncertain and include possible stent graft deterioration and
onset of aortic disease. They should be told of the need for
surveillance and possible further treatment.
Scientific evidence is currently of a low level. Random-
ized studies would be useful but are difficult to set up
because patient numbers are small and catchment areas are
very large. Data should be entered into a registry and be
part of a medical device vigilance study within the establish-
ment or be included prospectively in study currently com-
paring ESG with conventional surgery and medical treat-
ment, or both, similar to the design of the Investigation
of Stentgrafts in Aortic Dissection (INSTEAD) trial. A
registry of all thoracic aorta interventions, including
endovascular treatment, open surgery, thoracic ESG plus
JOURNAL OF VASCULAR SURGERY
May 20081106 Corbillon et alextra-anatomic bypass, and of follow-up data, accessible
to all practitioners and device manufacturers, would have
a number of advantages. It would (1) help identify the
profiles of patients suitable for ESG treatment, (2) assess
the practicability of a long-term randomized study com-
paring treatment modalities, (3) allow medium-term
assessment of different devices, and (4) provide informa-
tion for health economics studies.
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